Cleris L - Search Results

1

Verapamil potentiation of doxorubicin resistance development in B16 melanoma cells both in vitro and in vivo.

Formelli F, Supino R, Cleris L, Mariani M. Formelli F, et al. Among authors: cleris l. Br J Cancer. 1988 Apr;57(4):343-7. doi: 10.1038/bjc.1988.79. Br J Cancer. 1988. PMID: 3390370 Free PMC article.

2

Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour.

Acerbis G, Cleris L, Rodolfo M, Parmiani G, Formelli F. Acerbis G, et al. Among authors: cleris l. Cancer Immunol Immunother. 1992;34(6):383-8. doi: 10.1007/BF01741748. Cancer Immunol Immunother. 1992. PMID: 1563015 Free PMC article.

3

Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors.

Formelli F, Cleris L, Carsana R. Formelli F, et al. Among authors: cleris l. Cancer Chemother Pharmacol. 1988;21(4):329-36. doi: 10.1007/BF00264200. Cancer Chemother Pharmacol. 1988. PMID: 3370742

4

Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity.

Formelli F, Cleris L. Formelli F, et al. Among authors: cleris l. Cancer Res. 1993 Nov 15;53(22):5374-6. Cancer Res. 1993. PMID: 8221674

5

Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression.

Supino R, Crosti M, Clerici M, Warlters A, Cleris L, Zunino F, Formelli F. Supino R, et al. Among authors: cleris l. Int J Cancer. 1996 Feb 8;65(4):491-7. doi: 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D. Int J Cancer. 1996. PMID: 8621233

6

Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line.

Formelli F, Cleris L. Formelli F, et al. Among authors: cleris l. Eur J Cancer. 2000 Dec;36(18):2411-9. doi: 10.1016/s0959-8049(00)00335-x. Eur J Cancer. 2000. PMID: 11094318

7

Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.

Appierto V, Cavadini E, Pergolizzi R, Cleris L, Lotan R, Canevari S, Formelli F. Appierto V, et al. Among authors: cleris l. Br J Cancer. 2001 Jun 1;84(11):1528-34. doi: 10.1054/bjoc.2001.1826. Br J Cancer. 2001. PMID: 11384104 Free PMC article.

8

Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells.

Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C, Formelli F. Zuco V, et al. Among authors: cleris l. Cancer Lett. 2002 Jan 10;175(1):17-25. doi: 10.1016/s0304-3835(01)00718-2. Cancer Lett. 2002. PMID: 11734332

9

Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice.

Carlo-Stella C, Di Nicola M, Magni M, Longoni P, Milanesi M, Stucchi C, Cleris L, Formelli F, Gianni MA. Carlo-Stella C, et al. Among authors: cleris l. Cancer Res. 2002 Nov 1;62(21):6152-7. Cancer Res. 2002. PMID: 12414641

10

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.

le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C. le Coutre P, et al. Among authors: cleris l. J Natl Cancer Inst. 1999 Jan 20;91(2):163-8. doi: 10.1093/jnci/91.2.163. J Natl Cancer Inst. 1999. PMID: 9923858

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters